Trial Profile
An Open-Label, Randomised, Controlled, Multi-Centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-Old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC or INFANRIX-HEXA [Hib-DTaP-hepatitis B-poliovirus vaccine].
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors sanofi pasteur MSD
- 17 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.